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This study was designed to investigate the effects of glutathione (GSH) on delayed
vasospasm and the outcome of subarachnoid hemorrhage (SAH) patients.  Seventy-
seven SAH patients who were admitted to 4 hospitals and operated on within 72 h after
SAH, were injected intravenously with GSH (2.4 g/day) every 6 h for 14 days.  Seventy
SAH patients who were not treated with GSH in the same period were selected as the
control group.  Patient background, the outcome at 3 months after SAH according to
the Glasgow Outcome Scale and the occurrence of symptomatic vasospasm were in-
vestigated.  There were no statistically significant differences in patient backgrounds
between the 2 groups.  Regarding patient outcome, 57 patients (74%) showed good
recovery, 8 (10%) were moderately disabled, 9 (12%) were severely disabled, 2 (3%)
were in vegetative survival and 1 (1%) died in the GSH group, versus 39 (56%), 9
(13%), 15 (21%), 3 (4%) and 4 (6%) in the control group, respectively.  These overall
outcomes in the GSH group were significantly better than those in the control group (P
< 0.05).  In the GSH group, 31 patients (40%) showed symptomatic vasospasm, signif-
icantly lower than 46 (66%) in the control group (P < 0.01).  Administration of GSH
could be a good treatment for SAH patients.
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Although outcomes of patients who suffer from
subarachnoid hemorrhage (SAH) have been im-
proving over the last decade because of upgrad-
ing in microsurgical techniques and patient man-
agement, along with the development of vari-
ous anti-spasmogenic drugs, these outcomes are
not yet satisfactory to most neurosurgeons espe-
cially in elderly patients and patients graded
into the worse group according to their condi-
tions on admission.  Disney and colleagues
(1988) reported that 6 of 79 SAH patients (7.6%)
aged more than 60 years and 30 of 184 patients
(16.3%) classified as Grade III, IV or V on the
Hunt and Hess scale showed good recovery on
the Glasgow Outcome Scale at 3 months after
the onset.  Lipid peroxidations based on free
radical reactions were reported to increase in
the cerebrospinal fluid, vascular vessels and
serum after SAH and were thought to play a
pertinent role in the pathogenesis of delayed
cerebral vasospasm (Asano et al.,1981; Sasaki et
al.,1981a, 1981b; Romero et al.,1984; Shimizu et
al.,1988; Watanabe et al.,1988a, 1988b, 1992).
Recently in Japan, anti-lipid peroxidative drugs
or radical scavengers such as nizofenone fuma-
rate (Ohta et al., 1986), ozagrel natrium (Suzuki
et al., 1989), AVS [1,2-bis(nicotinamide)-
propane, (Asano et al., 1984, 1996)], ebselen
(Watanabe et al., 1990, 1997; Saito et al., 1998)
and MCI-186 [3-methyl-1-phenyl-pyrazolin-5-
one (Nakagome et al., 1990; Watanabe et al.,
1994)] have been applied to SAH patients to
prevent the occurrence of vasospasm and have
had some considerable effects on patient out-
comes.  These agents are however all artificial
and foreign to the human body.  Activation of
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natural anti-lipid peroxidative systems such as
the glutathione (GSH) cycle which are inherent
in living organisms was considered to lower the
lipid peroxide content and to have beneficial
effects on delayed vasospasm (Watanabe et al.,
1988b).  Reduced form GSH is converted to its
oxidized form by GSH peroxidase, reducing
lipid peroxides in the process and the oxidized
form GSH is converted back to GSH by GSH
reductase.  Administration of GSH was expect-
ed to reduce lipid peroxide levels, since it was
very difficult to increase these 2 enzyme activ-
ities.  We observed that GSH injected intra-
venously decreased lipid peroxide contents in
the serum and 5-lipoxygenase activity in the
basilar artery compared with the untreated
group and simultaneously ameliorated angio-
graphical delayed vasospasm of the basilar
artery in a canine two-hemorrhage model (un-
published data).  The present study was design-
ed to investigate the effects of GSH on delayed
cerebral vasospasm and the outcome of SAH
patients.  We administered GSH to SAH pa-
tients randomly and compared the findings with
data from patients who were not treated with
GSH.
Subjects and Methods
Patient Group
The SAH patients admitted to Tottori University
Hospital, Nojima Hospital, Tokyo Police Hospital
and National Yokohama Hospital between
January 1986 and January 1993 and underwent
clipping surgery within 72 h after SAH were
nominated for this study.  No patients were
ruled out in terms of sex, age, site of ruptured
aneurysm or clinical state before operation, the
only exception being a patient under 20 years
old.  The number of total SAH patients in the 4
hospitals in the above period was 478, of whom
291 were operated on within 72 h after SAH, 75
were operated on after 72 h, and 112 received
no operation.
Of the 291 candidates, 77 patients were se-
lected at random before surgery and treated
with 2.4 g/day of GSH after informed consent
was obtained.  Every 6 h, 0.6 g of GSH which was
dissolved with 100 mL of saline, was admini-
stered to the patient intravenously for 1 h.  This
treatment was started just after operation and
was continued for 14 days.  In this GSH group,
no other drugs which were generally accepted
as therapeutic against delayed vasospasm were
administered.  Temporary administration of cal-
cium antagonists and steroids for the purpose of
decreasing arterial blood pressure and reducing
brain swelling after the surgery were permitted.
As a control group, 70 patients were select-
ed randomly from the remaining 214 candi-
dates, retrospectively.  These patients were
treated with at least one of several therapeutics
such as nizofenone fumarate, ozagrel natrium,
AVS, Ebselen and MCI-186.
In both groups, no other aggressive treat-
ments such as cisternal perfusion therapy or
hypervolemic hypertensive therapy were per-
formed.
Clinical Assessment
After admission, each patient’s neurological
condition was assessed using the Japan Coma
Scale and/or the Glasgow Coma Scale, and the
presence or absence of paresis was assessed
every day and at any time when required.  The
patient’s state before the operation was graded
from I to V according to the World Federation
of Neurological Surgeons (WFNS) SAH scale
(Drake, 1988).
A computerized tomography (CT) scan was
taken on admission and classified according to
Fisher’s grouping (Fisher et al.,1980).  When
the patient’s state deteriorated due to rerupture
of the aneurysm before surgery, a further CT
scan was performed and was employed as a pre-
operative test.  Serial CT scans were done to
diagnose cerebral infarctions due to the vaso-
spasm.  The CT scan taken immediately after
the operation could reveal brain damage due to
surgery.
The site of the ruptured aneurysm was de-
termined from the results of the first cerebral
angiography, the CT scan and the operation.  In
most cases, the second angiography was per-
formed between Day 21 and Day 60, not to veri-
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fy the angiographical vasospasm but to confirm
the proper clipping of the aneurysmal neck.
Deterioration in the neurological conditions
of patients which occurred between Day 4 and
Day 16 was judged to be due to symptomatic
vasospasm when other possible causes such as
brain damage due to surgery, hydrocephalus,
serum electrolytes disorder, meningitis and epi-
lepsy were excluded.
Patient outcome was assessed 3 months
after SAH and was graded as good recovery,
moderately disabled, severely disabled, vegeta-
tive survival and dead by the Glasgow Outcome
Scale (GOS).
Statistical Analysis
The data based on the clinical variables from
the 2 groups were examined by Student’s t-test,
or the chi-squared test, or the Mann-Whitney U
test with the level of significance set at 0.05.
Table 1. Characteristics of patients in the 2 treatment groups
          Factor     GSH group  Control group P value
Number of patients 77 70
Sex 0.20
Male 40 (51.9) 29 (41.4)
Female 37 (48.1) 41 (58.6)
Age (year) 55.0  –  11.6 54.7  –  11.6 0.89
WFNS grade 0.13
I 29 (37.7) 35 (50.0)
II 19 (24.7) 15 (21.4)
III 4   (  5.2) 4 (  5.7)
IV 20 (26.0) 12 (17.1)
V 5 (  6.5) 4 (  5.7)
Location of ruptured aneurysm 0.70
Anterior communicating artery 26 (33.8) 21 (30.0)
Middle cerebral artery 25 (32.5) 22 (31.4)
Internal carotid artery 19 (24.7) 21 (30.0)
Anterior cerebral artery 3 (  3.9) 5 (  7.1)
Vertebral artery 3 (  3.9) 1 (  1.4)
Basilar artery 1 (  1.3) 0 (  0.0)
Fisher CT group 0.59
1 1 (  1.3) 0 (  0.0)
2 7 (  9.1) 14 (20.0)
3 49 (63.6) 36 (51.4)
4 20 (26.0) 20 (28.6)
Shown are number and (%), except age expressed as mean –  SD.
There were no statistically significant differences in patients’ backgrounds between the 2 groups.
CT, computerized tomography; GSH, glutathione; WFNS, World Federation of Neurological Surgeons.
Comparability of treatment groups
Distribution of sex, age in years, site of ruptured
aneurysm, preoperative WFNS grade and
Fisher’s preoperative grouping by CT scan in
both the GSH and the control groups are indi-
cated in Table 1.  As far as these factors were
concerned, there were no statistically signif-
icant differences between the 2 groups (P >
0.1).  P values were obtained by the use of the
chi-squared test for sex and site of ruptured
aneurysm, Student’s t-test for age, and the
Mann-Whitney U test for the WFNS grade and
Fisher grouping by CT, respectively (Table 1).
Symptomatic vasospasm and infarction
due to vasospasm
Table 2 shows the incidence of symptomatic
vasospasm and infarction due to vasospasm in
Results
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both groups.  The incidence of symptomatic
vasospasm in the GSH group was 31/77 (40%),
which was significantly lower than the value of
46/70 (66%) in the control group (P < 0.01, chi-
squared test).  Infarction due to vasospasm was
revealed on the CT scan in 22 cases (29%) in
the GSH group and 25 cases (36%) in the con-
trol group.  The difference between these fig-
ures was not statistically significant, although
the incidence of infarction due to vasospasm in
the GSH group was lower than that in the con-
trol group.
Patient outcome
Table 3 shows the patient outcome of both
groups in each preoperative WFNS grade.  In
all grades, 57 of the 77 patients (74%) in the
GSH group demonstrated good recovery at 3
Table 3. Outcome of all patients in the 2 treatment groups by WFNS grade
WFNS   Group      Good Moderately  Severely Vegetative   Dead
 grade    recovery   disabled  disabled   survival
I GSH 26 (89.7) 2 (  6.9) 1 (  3.4) 0 (  0.0) 0 (  0.0)
Control 30 (85.7) 2 (  5.7) 2 (  5.7) 1 (  2.9) 0 (  0.0)
II GSH* 18 (94.7) 0 (  0.0) 1 (  5.3) 0 (  0.0) 0 (  0.0)
Control* 6 (40.0) 2 (13.3) 7 (46.7) 0 (  0.0) 0 (  0.0)
III GSH 2 (50.0) 1 (25.0) 1 (25.0) 0 (  0.0) 0 (  0.0)
Control 2 (50.0) 1 (25.0) 1 (25.0) 0 (  0.0) 0 (  0.0)
IV GSH* 10 (50.0) 5 (25.0) 4 (20.0) 0 (  0.0) 1 (  5.0)
Control* 1 (  8.3) 4 (33.3) 4 (33.3) 0 (  0.0) 3 (25.0)
V GSH 1 (20.0) 0 (  0.0) 2 (40.0) 2 (40.0) 0 (  0.0)
Control 0 (  0.0) 0 (  0.0) 1 (25.0) 2 (50.0) 1 (25.0)
Total GSH* 57 (74.0) 8 (10.4) 9 (11.7) 2 (  2.6) 1 (  1.3)
Control* 39 (55.7) 9 (12.9) 15 (21.4) 3 (  4.3) 4 (  5.7)
Shown are number and (%).
GSH, glutathione; WFNS, World Federation of Neurological Surgeons.
Outcome was evaluated according to the Glasgow Outcome Scale.
* P < 0.05 by Mann-Whitney U test.
months in the GOS versus 39 of 70 patients
(56%) in the control group.  Regarding the
other outcomes, moderately disabled, se-
verely disabled, vegetative survival and
dead in the GSH group consisted of 8 pa-
tients (10%), 9 (12%), 2 (3%) and 1 (1%),
respectively, while these outcomes were
observed in 9 patients (13%), 15 (21%), 3
(4%) and 4 (6%) in the control group.  The
outcomes in WFNS grades II and IV and
also in all patients of the GSH group, were
significantly better than those of the control
group as shown in Table 3 (P < 0.05, Mann-
Whitney U test).  Figure 1 which shows patient
outcomes according to the GOS at 3 months is
divided into 2 classes, namely good recovery
and others (moderately disabled, severely dis-
abled, vegetative survival and dead) in each
preoperative WFNS grade.  The number of pa-
tients whose preoperative WFNS grade was I
and represented a good recovery outcome was
26 of 29 (90%) in the GSH group and 30 of 35
(86%) in the control group; and in the cases of
WFNS grades II, III, IV and V, 18 of 19 (95%),
2 of 4 (50%), 10 of 20 (50%) and 1 of 5 (20%)
showed good recovery at 3 months in the GSH
group versus 6 of 15 (40%), 2 of 4 (50%), 1 of
12 (8%) and 0 of 4 (0%) in the control group,
respectively.
Table 2. Incidence of symptomatic vasospasm
and infarction due to vasospasm in the 2 treat-
ment groups
Factor         Group
GSH Control
Symptomatic vasospasm 31* (40.3) 46*(65.7)
Infarction due to vasospasm 22 (28.6) 25 (35.7)
Shown are number and (%).
*P < 0.01 by chi-squared test.
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Fig. 1.  Bar graph showing outcomes of all patients in the
reduced form glutathione (GSH) and the control groups in
each preoperative World Federation of Neurological Surg-
eons (WFNS) grade.  Dark bars and light bars indicate good
recovery and the other outcomes based on the Glasgow Out-
come Scale, respectively.  The number of patients is indicated
in brackets.
Table 4. Outcome of elderly patients in the 2 treatment groups by WFNS grade
WFNS  Group   Good Moderately  Severely Vegetative   Dead
grade recovery   disabled  disabled   survival
I GSH 8 (80.0) 1 (10.0) 1 (10.0) 0 (  0.0) 0 (  0.0)
Control 4 (50.0) 1 (12.5) 2 (25.0) 1 (12.5) 0 (  0.0)
II GSH 5 (83.3) 0 (  0.0) 1 (16.7) 0 (  0.0) 0 (  0.0)
Control 3 (30.0) 2 (20.0) 5 (50.0) 0 (  0.0) 0 (  0.0)
III GSH 1 (50.0) 1 (50.0) 0 (  0.0) 0 (  0.0) 0 (  0.0)
Control 0 (  0.0) 1 (50.0) 1 (50.0) 0 (  0.0) 0 (  0.0)
IV GSH 2 (33.3) 1 (16.7) 2 (33.3) 0 (  0.0) 1 (16.7)
Control 0 (  0.0) 0 (  0.0) 3 (60.0) 0 (  0.0) 2 (40.0)
V GSH 1 (20.0) 0 (  0.0) 2 (40.0) 2 (40.0) 0 (  0.0)
Control 0 (  0.0) 0 (  0.0) 0 (  0.0) 2 (100.0) 0 (  0.0)
Total GSH* 17 (58.6) 3 (10.3) 6 (20.7) 2 (  6.9) 1 (  3.4)
Control* 7 (25.9) 4 (14.8) 11 (40.7) 3 (11.1) 2 (  7.4)
Shown are number and (%).
GSH, glutathione; WFNS, World Federation of Neurological Surgeons.
Outcome was evaluated according to the Glasgow Outcome Scale.  “ Elderly patients “ is defined as patients
aged 60 years or older.
* P < 0.05 by Mann-Whitney U test.
Vasospasm and outcome in elderly
patients
In elderly patients 60 years or older, the
incidence of symptomatic vasospasm in
the GSH group was 12/29 (41%) which
was significantly lower than 25/27
(93%) in the control group (P < 0.001,
chi-squared test).  Infarctions due to
delayed vasospasms as shown on the CT
scan occurred in 9 cases (31%) in the
GSH group and 14 cases (52%) in the
control group.  This difference was not
statistically significant.  Table 4 shows
the outcome of elderly patients in each
preoperative WFNS grade.  Concerning
all patients, 17 of 29 cases (59%) in the
GSH group and 7 of 27 cases (26%) in
the control group demonstrated good re-
covery at 3 months.  Regarding the other
classes of outcomes, moderately dis-
abled, severely disabled, vegetative sur-
vival and dead in the GSH group were
observed in 3  (10%), 6 (21%), 2 (7%)
and 1 case(s) (3%), respectively, while
these were observed in 4 (15%), 11
(41%), 3 (11%) and 2 cases (7%) in the control
group.  These outcomes in the GSH group were
significantly better than those in the control
group (P < 0.05, Mann-Whitney U test).  In
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each preoperative WFNS grade, the outcome in
the GSH group showed a tendency to be better
than that in the control group, although the
differences were not statistically significant.
As shown in Fig. 2, the ratio of the patients
whose outcomes were good recovery to the pa-
tients of the GSH group in each preoperative
WFNS grade seemed to be higher than that in
the control group.
Discussion
Although this was a retrospective study, the as-
sumption was that it was worthwhile to com-
pare the clinical outcomes of these 2 groups,
since there were no statistically significant
differences in the backgrounds among patients,
such as sex, age, preoperative WFNS grade, site
of ruptured aneurysm or Fisher’s grouping by
CT scan.  Of these factors, the patient’s pre-
Fig. 2.  Bar graph showing outcomes of elderly patients
aged over 60 in the reduced form glutathione (GSH) and the
control groups in each preoperative World Federation of
Neurological Surgeons (WFNS) grade.  Dark bars and light
bars indicate good recovery and the other outcomes based
on the Glasgow Outcome Scale, respectively.  The number
of patients is indicated in brackets.
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operative condition, amount and loca-
tion of subarachnoid clot, and patient’s
age were suggested to be crucial for
eventual outcome (Fisher et al., 1980;
Disney et al., 1988).  The mean age in
both groups was about 55 and almost
equal to each other.  The ratio of the
number of patients classified into
WFNS grades IV and V to all patients in
the GSH group was 33%, which was
higher than the 23% value in the control
group, although the P value in compar-
ing the 2 groups by the Mann-Whitney
U test was 0.13, which was rather low.
The incidence of Fisher’s groups 3 and 4
in the GSH group was 90% which was
higher than the 80% value in the control
group.  Thus, if the patient outcomes in
the GSH group would be better than
those in the control group, as indeed
they were, these results would be reli-
able, since the GSH group was at a dis-
advantage compared to the control
group in terms of the latter 2 factors.
Moreover, only GSH was administered
as an agent against delayed vasospasm
in the GSH group, while one or more
kinds of drugs were used in the control
group as mentioned above.
GSH has been applied to other kinds of
diseases such as hepatitis, toxicosis, toxemia of
pregnancy, exanthema, dermatitis, cataracts,
etc., but the cost for the administration of GSH
to SAH patients is not covered by health insur-
ance in Japan.  Therefore, it was impossible for
us to use GSH for all SAH patients.  This fortu-
nately enabled us to compare the outcome of the
GSH group with that of the control group.  GSH
is a drug which we can safely use for patients,
because it shows almost no side-effects such as
allergy, hypotension of arterial blood pressure
or platelet dysfunction.  Administration of GSH
for 14 days also costs far less than any other
treatment against vasospasm currently in use in
Japan.  This is and will be a very important mat-
ter regardless of whether the health insurance
system covers its use or not.
As shown in Tables 2 and 3, the administra-
tion of GSH for 2 weeks not only reduced the
GSH ameliorated outcome of SAH patients
79
incidence of symptomatic vasospasm but also
ameliorated the outcome in SAH patients, al-
though it did not significantly reduce the inci-
dence of infarction caused by delayed vasospasm.
Regarding each preoperative WFNS grade, pa-
tient outcomes in the GSH group in grades II
and IV were significantly better than those in
the control group as clearly shown in Fig. 1,
while there were no statistically significant dif-
ferences between the outcomes of the 2 groups
in grades I, III and V.  The numbers of patients
of both groups in grades III and V were 8 and 9,
respectively, which were too small to compare
statistically.  In grade I, 90% of patients in the
GSH group and 86% in the control group recov-
ered to the level of good recovery according to
the GOS at 3 months.  This suggests that patients
who suffered from mild SAH would recover
well irrespective of which drug is administered.
Also, in the elderly patients 60 years or
older, the administration of GSH significantly
reduced the incidence of symptomatic vaso-
spasm and ameliorated the clinical outcome,
but did not significantly reduce the incidence of
infarction due to vasospasm.  As shown in Fig.
2, GSH treatment tended to improve patient
outcome in each preoperative WFNS grade,
although there were no statistically significant
differences probably because of the small
number of cases.
In the younger patients under 60 and clas-
sified into preoperative WFNS grades I to III,
32 of 34 patients (94%) in the GSH group and
31 of 34 patients (91%) in the control group
showed an outcome at 3 months of good recov-
ery.  In the case of younger patients who were in
good condition after SAH, clinical outcomes
were already too good to be improved.  It may
be almost impossible for an agent against delay-
ed vasospasm to significantly ameliorate an
outcome of just 9% of patients, since these pa-
tients would suffer from surgical brain damage
and various kinds of complications at a certain
rate.  In WFNS grade IV, 8 of 14 younger pa-
tients (57%) in the GSH group and 1 of 7 pa-
tients (14%) in the control group showed good
recovery in the GOS.  In the younger and severe
SAH patients, GSH treatment tended to show
beneficial effects in patient outcome.
Good effects from GSH in outcomes were
observed in patients who were older than 60 or
suffered from severe SAH.  This has to be
stressed when we investigate effects of anti-
spasmogenic drugs on SAH patient outcomes.
Actually, Petruk and colleagues (1988) reported
that nimodipine treatment increased the rate of
good outcomes in poor-grade SAH patients in a
double-blind study, although Öhman and col-
leagues (1991) and Mercier and colleagues (1994)
reported that nimodipine treatment had no
effect on overall outcome in either good-grade
patients or all patients.  The mean ages in years
of SAH patients in recent studies were from 44
to 55 (Öhman et al., 1991; Haley et al., 1992,
1993, 1994; Shibuya et al., 1992), which were
equal to or lower than those in our study.  If the
mean age in our study would have been 45,
there might have been no statistically signifi-
cant difference in overall outcomes between the
GSH group and the control group.  The age of
SAH patients is becoming higher with the in-
creasing span of life; actually, the mean age of
SAH patients in Tottori University Hospital
was 64 in the past year.  We should thus make a
great effort to treat these elderly SAH patients
and should learn how to manage them effec-
tively.
Above all, the administration of GSH had
beneficial effects on not only the occurrence of
symptomatic vasospasm but also on the out-
come of the SAH patient, although the inci-
dence of infarction due to delayed vasospasm
was not significantly reduced by GSH treat-
ment.  In recent reports dealing with anti-
spasmogenic agents, nimodipine (Petruk et al.,
1988; Öhman et al., 1991; Mercier et al., 1994),
nicardipine (Haley et al., 1993), AT877 (Shibuya
et al., 1992), AVS (Asano et al., 1996) and
ebselen (Saito et al., 1998) could not alter the
overall outcome of SAH patients, although
these drugs had beneficial effects on some para-
meters such as symptomatic vasospasm, infarc-
tion shown on CT scan, etc.  These findings
revealed that these drugs could not only have
beneficial effects on delayed vasospasm but
also detrimental effects on patients, even if the
occurrence of delayed vasospasm could affect
only a small part of the outcome of SAH pa-
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tients.  Öhman and colleagues (1991) reported
results contrary to ours, namely that the admin-
istration of nimodipine reduced the incidence of
infarction due to delayed vasospasm but did not
ameliorate patient outcome.  These conflicting
results suggest that the occurrence of infarction
shown on CT scan could have a rather less ef-
fect on patient outcome according to the GOS.
Regarding the amount of GSH for SAH pa-
tients, we began with 2.4 g/patient/day, that is
1/5 of the dose (per body weight) with which
the experimental SAH dogs were treated, and
continued to use this dose for all patients.
Therefore we have no information concerning
the effects of other doses.  Lesser doses of GSH
may exert the same effects on vasospasm as ob-
served in this study, or higher doses may have
more effects than that in the case of 2.4 g/day.
In conclusion, intravenous administration of
2.4 g/day of GSH for 14 days ameliorated the
overall outcome of SAH patients, concomitant-
ly decreasing the incidence of symptomatic
vasospasm.  GSH can be used rather easily be-
cause of its rare detrimental effects and its low
cost, and GSH administration does not inhibit
any other treatments for SAH patients.  There-
fore, GSH treatment should be a good choice
for management of SAH patients, or at least this
should be added to treatments which have been
already available for such patients.
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